It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
The world is on the verge of an effective Ebola vaccine, the World Health Organization declared Friday. A vaccine being developed by Merck (NYSE: MRK) and NewLink Genetics (NASDAQ: NLNK) was shown to be 100 percent effective in preventing Ebola, according to an interim look from a late-stage study in Guinea.
The results need to be confirmed, but WHO Director-General Margaret Chan called them "an extremely promising development."
Does this mean Merck and NewLink are going to make big bucks? Not necessarily. And Merck says that wasn't its aim in the first place.
"Our motivation to pursue this opportunity was to address a public health need," Merck Vaccines' Mark Feinberg said in a telephone interview. "We did not believe this was a commercial opportunity."
The vaccine, which was originally developed by the Canadian government, continues in testing. The WHO said timing for potential licensing is uncertain, and noted there may be the possibility for stockpiling after that.
Feinberg said that could potentially generate a profit, though he added that it was too early to speculate further.
"From a business perspective, the technology that we have discovered and validated through the malaria (think they mean Ebola, a typo?) vaccine work is also very relevant to other vaccines," Slaoui said, pointing to a shingles vaccine that uses the same technology and which could be, in his words, more "economically impactful."....The company, Feinberg said, also invested "very significant resources of the time and effort of a large number of Merck staff who have worked tirelessly on this program." He pointed out a lot of funding came from external sources and governments.
Projects like this, Slaoui and Feinberg said, also engender a sense of purpose and pride among employees. "The opportunity to attract the best talent and retain them and inspire them is certainly something that is a core value at Merck," Feinberg said. "People at Merck genuinely identify with that and are proud their company pursues projects like that."
originally posted by: BELIEVERpriest
a reply to: Dark Ghost
What I want to know is, since when is a vaccine considered 100% effective. The flu shot has always been a hit or miss. Zostavax for shingles has a 50% success rate. How is it that Merck is suddenly able to crank out a miracle vax?
It doesn't seem koshur to me. I hope its true, but I find it very suspicious.
originally posted by: reldra
originally posted by: BELIEVERpriest
a reply to: Dark Ghost
What I want to know is, since when is a vaccine considered 100% effective. The flu shot has always been a hit or miss. Zostavax for shingles has a 50% success rate. How is it that Merck is suddenly able to crank out a miracle vax?
It doesn't seem koshur to me. I hope its true, but I find it very suspicious.
You're right. Can't possibly be 100% effective. There are several strains of Ebola.
originally posted by: DiddyMcC0y
a reply to: Dark Ghost
Im still not coming anywhere near the vaccine, id take my chance with Ebola
originally posted by: DiddyMcC0y
a reply to: Dark Ghost
Im still not coming anywhere near the vaccine, id take my chance with Ebola
originally posted by: Prezbo369
originally posted by: DiddyMcC0y
a reply to: Dark Ghost
Im still not coming anywhere near the vaccine, id take my chance with Ebola
And the Darwin award goes to....
originally posted by: Dark Ghost
Could it be true? Big Pharma interested more in saving lives than it is in turning over a profit? Call me cynical, but I find it difficult to believe that companies such as Merck are doing this solely for the benefit of humankind. I am not saying they are developing it only for materialistic gain, but it seems WAY too altruistic an action for Big Pharma.
I think they have realised we are on the verge of walking into there corporate offices and hanging the entire lot of them they are just corporate terrorists.